PL2735338T3 - Farmaceutyczne skojarzenie 3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu i pregabaliny lub gabapentyny - Google Patents

Farmaceutyczne skojarzenie 3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu i pregabaliny lub gabapentyny

Info

Publication number
PL2735338T3
PL2735338T3 PL14000597T PL14000597T PL2735338T3 PL 2735338 T3 PL2735338 T3 PL 2735338T3 PL 14000597 T PL14000597 T PL 14000597T PL 14000597 T PL14000597 T PL 14000597T PL 2735338 T3 PL2735338 T3 PL 2735338T3
Authority
PL
Poland
Prior art keywords
pregabalin
gabapentin
dimethylamino
phenol
propyl
Prior art date
Application number
PL14000597T
Other languages
English (en)
Inventor
Klaus Schiene
Petra Bloms-Funke
Thomas Christoph
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40345058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2735338(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL2735338T3 publication Critical patent/PL2735338T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL14000597T 2008-09-05 2009-09-04 Farmaceutyczne skojarzenie 3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu i pregabaliny lub gabapentyny PL2735338T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
EP09778335.1A EP2331210B1 (en) 2008-09-05 2009-09-04 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and an antiepileptic
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination
EP14000597.6A EP2735338B1 (en) 2008-09-05 2009-09-04 Pharmaceutical combination of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol and pregabalin or gabapentin

Publications (1)

Publication Number Publication Date
PL2735338T3 true PL2735338T3 (pl) 2019-07-31

Family

ID=40345058

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09778335T PL2331210T3 (pl) 2008-09-05 2009-09-04 Kombinacja farmaceutyczna 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu i środka przeciwpadaczkowego
PL14000597T PL2735338T3 (pl) 2008-09-05 2009-09-04 Farmaceutyczne skojarzenie 3-(3-dimetyloamino-1-etylo-2-metylopropylo)-fenolu i pregabaliny lub gabapentyny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL09778335T PL2331210T3 (pl) 2008-09-05 2009-09-04 Kombinacja farmaceutyczna 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu i środka przeciwpadaczkowego

Country Status (28)

Country Link
US (1) US20100063148A1 (pl)
EP (2) EP2735338B1 (pl)
JP (4) JP5731387B2 (pl)
KR (3) KR101730924B1 (pl)
CN (2) CN102159284B (pl)
AR (2) AR073361A1 (pl)
AU (3) AU2009289776A1 (pl)
BR (1) BRPI0920521A2 (pl)
CA (1) CA2735857C (pl)
CL (1) CL2011000317A1 (pl)
CO (1) CO6382142A2 (pl)
CY (2) CY1115751T1 (pl)
DK (2) DK2331210T3 (pl)
EC (1) ECSP11010869A (pl)
ES (2) ES2719900T3 (pl)
HR (2) HRP20140663T1 (pl)
HU (1) HUE043278T2 (pl)
IL (3) IL211135A (pl)
LT (1) LT2735338T (pl)
MX (1) MX2011002339A (pl)
PE (5) PE20142371A1 (pl)
PL (2) PL2331210T3 (pl)
PT (2) PT2331210E (pl)
RU (2) RU2571501C2 (pl)
SI (2) SI2735338T1 (pl)
TR (1) TR201904388T4 (pl)
WO (1) WO2010025931A2 (pl)
ZA (1) ZA201101449B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
RU2589692C2 (ru) * 2010-06-15 2016-07-10 Грюненталь Гмбх Фармацевтическая комбинация для лечения от боли
EP2590636A1 (en) 2010-07-06 2013-05-15 Grünenthal GmbH Novel gastro- retentive dosage forms comprising a gaba analog and an opioid
MX2013000946A (es) 2010-07-30 2013-02-27 Toray Industries Agente terapeutico o agente profilactico para el dolor neuropatico.
MX348831B (es) * 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
ES2712072T3 (es) * 2011-07-20 2019-05-09 Torrent Pharmaceuticals Ltd Composición farmacéutica de tapentadol
JP6038138B2 (ja) * 2011-07-29 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−［（１ｓ，２ｓ）−３−（ジメチルアミノ）−１−エチル−２−メチルプロピル］フェノールのくも膜下投与または硬膜外投与
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9855286B2 (en) * 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
JP6360488B2 (ja) * 2012-11-01 2018-07-18 トレント・ファーマシューティカルズ・リミテッドＴｏｒｒｅｎｔ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｉｍｉｔｅｄ 非経口投与のためのタペンタドールの薬学的組成物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
EP3800177B1 (en) 2015-12-22 2025-01-29 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
JP2019507111A (ja) 2015-12-22 2019-03-14 ゾゲニクス インターナショナル リミテッド 代謝抵抗性フェンフルラミン類縁体およびその使用法
RU2021106383A (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
WO2019216919A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EA202191079A1 (ru) 2018-11-19 2021-09-20 Зодженикс Интернэшнл Лимитед Способы лечения синдрома ретта с применением фенфлурамина
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
IL148019A0 (en) * 1999-08-20 2002-09-12 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and an anticonvulsant drug
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
PL372210A1 (pl) * 2002-02-22 2005-07-11 Warner-Lambert Company Llc Połączenia alfa-2-delta ligandu z selektywnym inhibitorem cyklooksygenazy-2
WO2007005716A2 (en) 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
HRP20110271T1 (hr) * 2006-04-28 2011-05-31 Grnenthal Gmbh Farmaceutska kombinacija koja sadrži 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol i nsaid (nesteroidni antiinflamatorni lijek)
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP2219633A2 (en) * 2007-11-23 2010-08-25 Nectid, Inc. Tapentadol compositions
EP2250143B1 (en) * 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
KR101730924B1 (ko) * 2008-09-05 2017-04-27 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물

Also Published As

Publication number Publication date
JP5731387B2 (ja) 2015-06-10
DK2735338T3 (en) 2019-04-23
HRP20190500T1 (hr) 2019-08-09
KR101641519B1 (ko) 2016-07-21
CY1121492T1 (el) 2020-05-29
JP2017071636A (ja) 2017-04-13
IL237392A0 (en) 2015-04-30
MX2011002339A (es) 2011-04-04
ES2513394T3 (es) 2014-10-27
HK1198145A1 (en) 2015-03-13
WO2010025931A2 (en) 2010-03-11
KR101730924B1 (ko) 2017-04-27
WO2010025931A3 (en) 2010-06-17
SI2331210T1 (sl) 2014-10-30
PE20142357A1 (es) 2015-02-04
PT2331210E (pt) 2014-08-25
CA2735857A1 (en) 2010-03-11
ES2719900T3 (es) 2019-07-16
KR101851120B1 (ko) 2018-04-23
LT2735338T (lt) 2019-04-10
KR20160086981A (ko) 2016-07-20
CN105520924A (zh) 2016-04-27
AU2009289776A1 (en) 2010-03-11
IL237391A (en) 2017-12-31
AU2016203053B2 (en) 2018-01-25
JP2012501986A (ja) 2012-01-26
KR20170048602A (ko) 2017-05-08
IL211135A (en) 2017-09-28
CN105520924B (zh) 2019-04-09
PE20142372A1 (es) 2015-02-04
HUE043278T2 (hu) 2019-08-28
PL2331210T3 (pl) 2014-12-31
CN102159284A (zh) 2011-08-17
IL211135A0 (en) 2011-04-28
IL237392B (en) 2019-08-29
TR201904388T4 (tr) 2019-05-21
AR117613A2 (es) 2021-08-18
KR20110057144A (ko) 2011-05-31
ZA201101449B (en) 2011-10-26
PT2735338T (pt) 2019-05-24
JP2015096530A (ja) 2015-05-21
PE20110291A1 (es) 2011-06-04
EP2331210A2 (en) 2011-06-15
AU2018202879A1 (en) 2018-05-17
CL2011000317A1 (es) 2011-06-17
EP2735338A1 (en) 2014-05-28
AU2016203053A1 (en) 2016-06-02
AR073361A1 (es) 2010-11-03
CA2735857C (en) 2019-05-28
US20100063148A1 (en) 2010-03-11
CN102159284B (zh) 2015-12-09
PE20190914A1 (es) 2019-06-26
SI2735338T1 (sl) 2019-04-30
EP2331210B1 (en) 2014-07-09
HK1159011A1 (en) 2012-07-27
BRPI0920521A2 (pt) 2018-01-16
EP2735338B1 (en) 2019-02-06
PE20142371A1 (es) 2015-02-04
ECSP11010869A (es) 2011-04-29
IL237391A0 (en) 2015-04-30
DK2331210T3 (da) 2014-08-11
JP2019131578A (ja) 2019-08-08
RU2674150C1 (ru) 2018-12-05
HRP20140663T1 (hr) 2014-10-10
AU2018202879B2 (en) 2020-03-12
CY1115751T1 (el) 2017-01-25
CO6382142A2 (es) 2012-02-15
RU2011112444A (ru) 2012-10-10
RU2571501C2 (ru) 2015-12-20

Similar Documents

Publication Publication Date Title
LT2735338T (lt) 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolio ir pregabalino arba gabapentino farmacinis derinys
ZA201102762B (en) CO-CRYSTALS OF TRAMADOL AND NSAIDs
EP2445340A4 (en) SUBSTITUTED HYDROXAMINE ACIDS AND USES THEREOF
BRPI0909750A2 (pt) dispositivo e cápsula para a preparação de uma bebida
IL210318A (en) Acetylation fatty acid salicylates and their uses
GB201013420D0 (en) Slowness-frequency projection display and animation
PT2474522E (pt) Agomelatina e composições farmacêuticas que contêm a mesma
PL2519100T3 (pl) Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
ZA201202151B (en) Compositions comprising tramadol and celecoxib in the treatment of pain
ZA200905698B (en) Solid forms comprising (-) O-desmethylvenlafaxine and uses thereof
EP2358658A4 (en) PREPARATION OF RASAGILIN AND ITS SALTS
ZA200905688B (en) Fungicidal mixtures of 1-Methylpyrazole-4-Ylcarboxylic acid anilides and azolopy-rimidinylamines
IL214355A0 (en) Antibodies against human tweak and uses thereof
IL207508A0 (en) Dosage forms comprising gabapentin and a hydrophillic polymer and uses thereof
IL209698A (en) Use of Niportimox for the preparation of pharmaceuticals and preparations containing this Niportimox
PT2117519E (pt) Composição farmaceutica compreendendo tramadol e cetoprofeno
IL213711A0 (en) Pharmaceuticl formulation of nanonised fenofibrate
IL213128A0 (en) Processes for the preparation and purification of gabapentin enacarbil
PL2247752T3 (pl) Przewidywanie i diagnozowanie mielopatii zwyrodnieniowej psów
ZA201101669B (en) Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol
GB0819293D0 (en) Radiofluorination
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
IL206555A (en) Array decoder
HK1160035A (en) Co-crystals of tramadol and nsaids
HU0800091D0 (en) Novel polymorphs and amorph forms of desvenlafaxine fumarate